Archive: 17/01/2019
First clinical study shows mavoglurant improves eye gaze behavior in fragile X syndrome patients
Researchers at Rush University Medical Center and the MIND Institute at UC Davis have found that mavoglurant, an experimental drug known as an mGluR5 negative modulator, can positively modify a key characteristic behavior ...
Jan 17, 2019